Anti-nuclear matrix protein 2 antibody-associated juvenile dermatomyositis with gastrointestinal perforations was successfully treated with traditional therapeutic drugs combined with vedolizumab: a case report after a long-term follow-up and a review of the literature

Xue-mei Xu, Shuang Ye, Ying-ying Jin, Chen-xi Liu, Sheng-fang Bao, Hua Huang, Fei Ding, Zhen Yang, Yan-liang Jin · 2025

Read Anti-nuclear matrix protein 2 antibody-associated juvenile dermatomyositis with gastrointestinal perforations was successfully treated with traditional therapeutic drugs combined with vedolizumab: a case report after a long-term follow-up and a review of the literature by Xue-mei Xu, Shuang Ye, Ying-ying Jin, Chen-xi Liu, Sheng-fang Bao, Hua Huang, Fei Ding, Zhen Yang, Yan-liang Jin (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11788329.txt.

Description

Xue-mei Xu and co-authors report a hard case of a childhood muscle disease with gut perforation, and review past cases, in a paper from 2024. The disease, juvenile dermatomyositis, inflames muscles and skin in children. In rare, severe cases the gut wall breaks open, which can kill. Standard strong immune drugs do not always save such patients.

Their patient developed a gut perforation five months after diagnosis, with a marker antibody tied to severe disease. Alongside standard drugs, the team added vedolizumab, a gut-focused immune drug. The child recovered, and long-term follow-up held up well. The review found 29 more cases in print by late 2023. Care there leaned on steroids and a long list of immune drugs. The authors offer the added drug as a fresh option for the worst cases.

Catalog record

CREATORXue-mei Xu, Shuang Ye, Ying-ying Jin, Chen-xi Liu, Sheng-fang Bao, Hua Huang, Fei Ding, Zhen Yang, Yan-liang Jin
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE20 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11788329

Browse the full library · About the Tower of Babel